ResearcherSun Yat-sen UniversityNo recent work listed
Yuanfeng Gong
Matched on ORCID iD 0000-0001-7742-6286; OpenAlex author ID A5005757913. Sources: OpenAlex.
Their work
- Papers
- 9
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 4 papers
Papers 9
- Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2021/6682697↗
- Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.1155/2021/9949272↗
- Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. Co-author DOI 10.1177/11795549211024149↗
- CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. Co-author DOI 10.7150/jca.57082↗
- B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer. Co-author DOI 10.18632/aging.202255↗
- Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis. Co-author DOI 10.3390/nu9040394↗
- Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy. Co-author DOI 10.3892/ol.2017.5717↗
- Cholelithiasis and risk of pancreatic cancer: systematic review and meta-analysis of 21 observational studies. Co-author DOI 10.1007/s10552-014-0458-3↗
- Gastrectomy and risk of pancreatic cancer: systematic review and meta-analysis of observational studies. Co-author DOI 10.1007/s10552-012-0005-z↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chuanzhao Zhang · 5 shared papers, 2020–2021 · strength 0.60
- Paper CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. DOI 10.7150/jca.57082↗
- Paper Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. DOI 10.1177/11795549211024149↗
- Paper Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2021/6682697↗
- Hongkai Zhuang · 5 shared papers, 2020–2021 · strength 0.60
- Paper CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. DOI 10.7150/jca.57082↗
- Paper Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. DOI 10.1177/11795549211024149↗
- Paper Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2021/6682697↗
- Shanzhou Huang · 5 shared papers, 2020–2021 · strength 0.60
- Paper CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. DOI 10.7150/jca.57082↗
- Paper Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. DOI 10.1177/11795549211024149↗
- Paper Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2021/6682697↗
- Zuyi Ma · 5 shared papers, 2020–2021 · strength 0.60
- Paper CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. DOI 10.7150/jca.57082↗
- Paper Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. DOI 10.1177/11795549211024149↗
- Paper Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2021/6682697↗
- Zixuan Zhou · 5 shared papers, 2020–2021 · strength 0.60
- Paper CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. DOI 10.7150/jca.57082↗
- Paper Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. DOI 10.1177/11795549211024149↗
- Paper Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2021/6682697↗
- Baohua Hou · 5 shared papers, 2020–2021 · strength 0.60
- Paper CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. DOI 10.7150/jca.57082↗
- Paper Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. DOI 10.1177/11795549211024149↗
- Paper Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2021/6682697↗
- Zhenchong Li · 4 shared papers, 2021 · strength 0.48
- Paper CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. DOI 10.7150/jca.57082↗
- Paper Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. DOI 10.1177/11795549211024149↗
- Paper Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2021/6682697↗
- Yiping Zou · 2 shared papers, 2021 · strength 0.23
- Bowen Huang · 2 shared papers, 2021 · strength 0.23
- Shujie Wang · 1 shared paper, 2021 · strength 0.12
- Bo Chen · 1 shared paper, 2021 · strength 0.12
- Quanbo Zhou · 2 shared papers, 2012–2017 · strength 0.11
- Rufu Chen · 2 shared papers, 2012–2017 · strength 0.11
- Qi Zhou · 1 shared paper, 2021 · strength 0.11
- Hui Tang · 1 shared paper, 2017 · strength 0.08
- Hui Tang · 1 shared paper, 2014 · strength 0.05
- Zhihua Li · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.